Literature DB >> 24088105

Eculizumab in atypical hemolytic-uremic syndrome.

Christophe M Legendre, Christoph Licht, Chantal Loirat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24088105     DOI： 10.1056/NEJMc1308826

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  28 in total

1.  Platelets are relevant mediators of renal injury induced by primary endothelial lesions.

Authors:  Claudia Schwarzenberger; Jan Sradnick; Kenneth M Lerea; Michael S Goligorsky; Bernhard Nieswandt; Christian P M Hugo; Bernd Hohenstein
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-01

2.  Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.

Authors:  Arthur J Vaught; Eleni Gavriilaki; Nancy Hueppchen; Karin Blakemore; Xuan Yuan; Sara M Seifert; Sarah York; Robert A Brodsky
Journal:  Exp Hematol       Date:  2016-02-26       Impact factor: 3.084

3.  Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency.

Authors:  Katell Michaux; Justine Bacchetta; Etienne Javouhey; Pierre Cochat; Véronique Frémaux-Bacchi; Anne-Laure Sellier-Leclerc
Journal:  Pediatr Nephrol       Date:  2014-08-23       Impact factor: 3.714

4.  Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.

Authors:  S Vasu; H Wu; A Satoskar; M Puto; J Roddy; W Blum; R Klisovic; L Andritsos; C Hofmeister; D M Benson; Y Efebera; S Jaglowski; S Penza; D Cohen; S Devine; S Cataland
Journal:  Bone Marrow Transplant       Date:  2016-04-11       Impact factor: 5.483

5.  Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab.

Authors:  Renuka Shanmugalingam; Danny Hsu; Angela Makris
Journal:  Obstet Med       Date:  2017-05-18

6.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

7.  Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.

Authors:  Fadi Fakhouri; Marc Fila; François Provôt; Yahsou Delmas; Christelle Barbet; Valérie Châtelet; Cédric Rafat; Mathilde Cailliez; Julien Hogan; Aude Servais; Alexandre Karras; Raifah Makdassi; Feriell Louillet; Jean-Philippe Coindre; Eric Rondeau; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-31       Impact factor: 8.237

Review 8.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 9.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

10.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.